英雄横幅 - 图像

TOGETHER, WE'VE GOT THIS.

Patients Can't Wait. Neither Can We.™

学到更多

智能手机的图象

A Transformational Approach to Clinical Trials

LabCorp Transforms the Clinical Trial Experience to Streamline its Drug Development Process

Company goes beyond decentralized clinical trials to deliver seamless tech-enabled, patient-centric enterprise solutions. LabCorp now offers a comprehensive and fully integrated patient, site, and customer experience for DCTs.

A NEW AND INNOVATIVE APPROACH TO RECRUITMENT OF ONCOLOGY PATIENTS

Covance and Tempus Have Joined Forces to Accelerate Patient Recruitment in Biomarker-Driven Studies

We are expanding our patient-centric approach to recruitment by incorporating the Tempus Integrated Molecular Evaluation (TIME) Trial™ Program. Learn more about how our combined recruitment capabilities can screen and match patients to biomarker trials to open a site in as few as 10 days.

Covance announces acquisition of snapIoT

Covance announces acquisition of snapIoT

Covance announces acquisition of snapIoT

LabCorp has announced that Covance has completed the transaction to acquire snapIoT, the fastest growing platform as a service provider of mobile-connected self-service platform solutions. This acquisition enables Covance to offer highly configurable and inter-operable patient centric solutions that enable remote participation in clinical trials, reduce patient burden while speeding implementation and improving data quality.

我们在一起

COVID-19

Whether you are developing a COVID-19 assay, a vaccine to prevent patients from getting COVID-19, an antiviral or a treatment to mitigate the severe immunological response (cytokine storm) associated with COVID-19, we can partner with you to provide critical drug development and diagnostic services to address the global pandemic.

News

Covance Announces Acquisition of GlobalCare Clinical Trials, LLC

Labcorp宣布,Covance已完成交易,以获得全球公认的分散临床试验(DCT)的全球公认的行业领导者。收购GlobalCare将扩大董事会DCTS提供进入全球市场的COT,并帮助我们满足您对患者为中心的试验设计的不断增长的需求。

Covance Innovation

Patients can’t wait. And neither can we™

The healthcare industry is always looking to the future... to discover a better treatment... to deliver a cure... to prevent disease…to improve quality of life. And it’s our mission to help speed that process. What matters is not “how it’s always been done,” but how it can be done now. Better. And Faster. Through new approaches explored, ideas perfected, and transformational thinking.

# COVANCEPOTENTIAL

It's not just a job. To us, it's personal.

Covance, the drug development business of LabCorp, is recognized as a leader in drug development because of our exceptional people. We embrace and celebrate the different strengths, experiences and perspectives of our 65,000+ enterprise team members across the globe. Our team is driven by an energizing purpose to improve health and improve lives. Here, you can play a role in bringing new scientific discoveries to life and make a difference in the lives of millions. Join us and discover your extraordinary potential.

Covance by the Numbers

年度遭遇 160M Patients
Supports Clinical Trials in 100+ 国家
合作 100% 新型肿瘤药物
帮助发展 86% 罕见的孤儿药

Contributed in the development of all the current top 50 drugs on the market

Covance Insights

COVID-19: vaccine innovation and safety at pandemic speed
COVID-19: vaccine innovation and safety at pandemic speed
Blogs
The global spread of COVID-19 and its great impact on the health and wellbeing of our population has imposed a race to develop an effective vaccine at unprecedented speed. A development process that usually spans several years is being compressed into one year - or less. Safety is a vital part of this process, and so we identified and discussed several key factors and considerations around safety in vaccine development. This article provides a synopsis of our insights.
阅读更多
Closing the Gap in Pediatric Oncology Drug Development: The Regulatory Landscape and the RACE for Children Act
Closing the Gap in Pediatric Oncology Drug Development: The Regulatory Landscape and the RACE for Children Act
白皮书
The current regulatory environment can help support sponsors with the complex efforts involved in pediatric oncology drug development, as regulatory agencies and legislative acts have helped encourage, incentivize or even require the conduct of pediatric trials in other indications. This white paper provides a brief history of how pediatric cancer treatments have progressed, outlines how regulatory changes have impacted the field of pediatric drug development and provides guidance on applying current regulations, such as the RACE for Children Act which is focused on pediatric oncology. This change should serve to enhance an inclusive regulatory strategy for oncologic drug development.
阅读更多
医疗设备和诊断解决方案:临床前与实验手术yaboapp体育官网
医疗设备和诊断解决方案:临床前与实验手术yaboapp体育官网
小册子
通过与我们的医疗设备开发专家合作来制yaboapp体育官网作最佳临床前策略。然后访问使您的初始开发阶段更容易yaboapp体育官网所需的临床前资源。无论您是探索有前途的设备概念,启动全面的检测计划或进行单一学习,Covance医疗设备和诊断解决方案都可以帮助您在最早的发展阶段证明您的设备。
阅读更多
Patient-Centric Field Reimbursement Quadruples Enrollment, Increases Stakeholder Satisfaction
Patient-Centric Field Reimbursement Quadruples Enrollment, Increases Stakeholder Satisfaction
实例探究
前5名制药公司与密码合作,为其自身免疫性输液治疗计划提供现场报销管理(FRM)服务。了解有关Covance如何在促进入学和利益相关者满意度方面发挥着关键作用的更多信息。
阅读更多

及时了解Covance的最新消息

Subscribe Now

学到更多